Dow Today: Merck (MRK) Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading up 52 points (+0.3%) at 17,128 as of Tuesday, Aug 26, 2014, 12:36 p.m. ET. During this time, 95.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 299.6 million. The NYSE advances/declines ratio sits at 1,998 issues advancing vs. 975 declining with 164 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be Merck (NYSE: MRK), which is sporting a 59-cent gain (+1%) bringing the stock to $60.32. This single gain is lifting the Dow Jones Industrial Average by 4.47 points or roughly accounting for 8.6% of the Dow's overall gain. Volume for Merck currently sits at five million shares traded vs. an average daily trading volume of 8.2 million shares.

Merck has a market cap of $170.68 billion and is part of the health care sector and drugs industry. Shares are up 19.3% year-to-date as of Monday's close. The stock's dividend yield sits at 3%.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Imagining the Stock Market in 10 Years

Imagining the Stock Market in 10 Years

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific